Our study has several strengths: (i) it is the first analysis of a patient population not treated with systemic adjuvant therapy which allows for assessment of the pure prognostic effect without potential predictive interactions, (ii) this analysis is – to the best of our knowledge – the first to examine the correlation of CRP values with the expression of a multitude of genes in the corresponding carcinomas of the breast. The gene discussed is CRP; the disease is breast carcinoma.